Cisplatin Resistance Associated with PARP Hyperactivation

Global cancer statistics

Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634

Mitochondrial membrane permeabilization in cell death

Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598

Molecular mechanisms of cisplatin resistance

Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions

D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819

Principles of cancer therapy: oncogene and non-oncogene addiction

Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

Modulation of oxidative stress as an anticancer strategy

Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579

Systems biology of cisplatin resistance: past, present and future

Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782

The multifaceted role of reactive oxygen species in tumorigenesis

Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer

Fennell, D. A., Summers, Y., Cadranel, J. L., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren‐Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382

Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy

Yamazaki, T., Kirchmair, A., Sato, A., Buqué, A., Rybstein, M., Petroni, G., Bloy, N., Finotello, F., Stafford, L., Navarro Manzano, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0751-0 · Cited by 359

Trial watch: IDO inhibitors in cancer therapy

Vacchelli, E., Aranda, F., Eggermont, A. M. M., Sautès‐Fridman, C., Tartour, É., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 333

Advances in PET imaging of cancer

Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 343

Trial watch: STING agonists in cancer therapy

Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289

Molecular mechanisms of regulated necrosis

Galluzzi, L., Kepp, O., Krautwald, S., Kroemer, G., & Linkermann, A. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.02.006 · Cited by 258

Trial watch: TLR3 agonists in cancer therapy

Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239

Trapping Poly(ADP-Ribose) Polymerase

Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230

Chloroquine and hydroxychloroquine for cancer therapy

Manic, G., Obrist, F., Kroemer, G., Vitale, I., & Galluzzi, L. (2014) · Molecular & Cellular Oncology · doi:10.4161/mco.29911 · Cited by 231

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 224

Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer

Colombo, P., Fabbro, M., Theillet, C. G., Bibeau, F., Rouanet, P., & Ray-Coquard, I. L. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.017 · Cited by 193

Trial watch: IDO inhibitors in cancer therapy

Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 195

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175

Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162

The role of DNA repair pathways in cisplatin resistant lung cancer

O’Grady, S., Finn, S. P., Cuffe, S. D., Richard, D. J., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.003 · Cited by 154

Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients

Rodriguez-Ruiz, M. E., Buqué, A., Hensler, M., Chen, J., Bloy, N., Petroni, G., Sato, A., Yamazaki, T., Fucikova, J., & Galluzzi, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655964 · Cited by 147

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy

Manic, G., Obrist, F., Sistigu, A., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1012976 · Cited by 152

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0247 · Cited by 149

The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma

Tufo, G., Jones, A. W. E., Wang, Z., Hamelin, J., Tajeddine, N., Esposti, D. D., Martel, C., Boursier, C., Gallerne, C., Migdal, C., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.193 · Cited by 139

Current status of poly(ADP-ribose) polymerase inhibitors and future directions

Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 131

Targeting DNA repair pathway in cancer: Mechanisms and clinical application

Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 140

Metabolic vulnerability of cisplatin‐resistant cancers

Obrist, F., Michels, J., Durand, S., Chery, A., Pol, J. G., Lévesque, S., Joseph, A., Astesana, V., Pietrocola, F., Wu, G. S., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798597 · Cited by 122

PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?

Swindall, A. F., Stanley, J. A., & Yang, E. S.-H. (2013) · Cancers · doi:10.3390/cancers5030943 · Cited by 123

Trial Watch

Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 116

Predictive biomarkers for cancer therapy with PARP inhibitors

Michels, J., Vitale, I., Saparbaev, M. K., Castedo, M., & Kroemer, G. (2013) · Oncogene · doi:10.1038/onc.2013.352 · Cited by 117

Immunotherapy in Cervical Cancer

Mauricio, D., Zeybek, B., Tymon‐Rosario, J., Harold, J. A., & Santin, A. D. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01052-8 · Cited by 118

PARP1 Inhibitors: Antitumor Drug Design

Maluchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., & Studitskiy, V. M. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-3-27-37 · Cited by 112

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

Cheng, H., Zhang, Z., Barrueco, R. R., Borczuk, A., Liu, H., Yu, J., Silva, J. M., Cheng, S. K., Perez-Soler, R., & Halmos, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6721 · Cited by 93

FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1

Wu, X., Dong, Z., Wang, C. J., Barlow, L., Fako, V. E., Serrano, M. A., Zou, Y., Liu, J., & Zhang, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609934113 · Cited by 93

Extracorporeal photochemotherapy induces bona fide immunogenic cell death

Tatsuno, K., Yamazaki, T., Hanlon, D. J., Han, P., Robinson, E., Sobolev, O., Yurter, A., Rivera-Molina, F. E., Arshad, N., Edelson, R. L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1819-3 · Cited by 94

Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities

Wang, M., Xiao, Y., Miao, J., Zhang, X., Liu, M., Zhu, L., Liu, H., Shen, X., Wang, J., Xie, B., et al. (2025) · Antioxidants · doi:10.3390/antiox14060735 · Cited by 101

Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property

Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-13232-3 · Cited by 84

Profile of veliparib and its potential in the treatment of solid tumors

Wagner, L. M. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s69935 · Cited by 80

PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies

Michel, L. S., Dyroff, S. L., Brooks, F. J., Spayd, K. J., Lim, S., Engle, J. T., Phillips, S. E., Tan, B. R., Wang‐Gillam, A., Bognar, C., et al. (2016) · Radiology · doi:10.1148/radiol.2016161929 · Cited by 78

Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

Fischer, C., Leithner, K., Wohlkoenig, C., Quehenberger, F., Bertsch, A., Olschewski, A., Olschewski, H., & Hrzenjak, A. (2015) · Molecular Cancer · doi:10.1186/1476-4598-14-4 · Cited by 77

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

Yarchoan, M. M., Myzak, M. C., Johnson, B. A., Jesus‐Acosta, A. D., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 78

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Michels, J., Vitale, I., Senovilla, L., Enot, D. P., Garcia, P., Lissa, D., Olaussen, K. A., Brenner, C., Soria, J., Castedo, M., et al. (2013) · Cell Cycle · doi:10.4161/cc.24034 · Cited by 78

Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B

El‐Senduny, F. F., Badria, F. A.-E., El‐Waseef, A. M., Chauhan, S. C., & Halaweish, F. T. (2015) · Tumor Biology · doi:10.1007/s13277-015-3773-8 · Cited by 76

Cytotoxicity of Pyrazine-Based Cyclometalated (C^Npz^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties

Bertrand, B., Fernández‐Cestau, J., Angulo, J., Cominetti, M. M. D., Waller, Z. A. E., Searcey, M., O'Connell, M. A., & Bochmann, M. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.7b00339 · Cited by 77

IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules

Duan, S., Tsai, Y., Keng, P., Chen, Y., Lee, S. O., & Chen, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4753 · Cited by 71

The Evolution of STING Signaling and Its Involvement in Cancer

Vashi, N., & Bakhoum, S. F. W. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.12.010 · Cited by 72

Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells

Wang, H., Shan, Z., Song, L., Qu, M., & Zou, Z. (2020) · Oncogene · doi:10.1038/s41388-020-1191-x · Cited by 72

MCL-1 dependency of cisplatin-resistant cancer cells

Michels, J., Obrist, F., Vitale, I., Lissa, D., Garcia, P., Behnam‐Motlagh, P., Kohno, K., Wu, G. S., Brenner, C., Castedo, M., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.029 · Cited by 68

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

Reinbolt, R. E., & Hays, J. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00237 · Cited by 62

C‐Jun N‐terminal kinase signalling pathway in response to cisplatin

Yan, D., An, G., & Kuo, M. T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12908 · Cited by 61

PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair

Choi, E.-B., Yang, A.-Y., Kim, S. C., Lee, J., Choi, J. K., Choi, C., & Kim, M. Y. (2016) · Oncogene · doi:10.1038/onc.2016.3 · Cited by 59

Natural Product Modulators to Overcome Multidrug Resistance In Cancer

Çört, A., & Özben, T. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1002624 · Cited by 56

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells

Caiola, E., Salles, D. C., Frapolli, R., Lupi, M., Rotella, G., Ronchi, A., Garassino, M. C., Mattschas, N. A. L., Colavecchio, S., Broggini, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5019 · Cited by 52

Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy

Lu, Y., Liu, Y., Pang, Y. K., Pacák, K., & Yang, C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.006 · Cited by 51

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

Yusoh, N. A., Ahmad, H., & Gill, M. R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000391 · Cited by 52

A Double-Edged Sword: The Two Faces of PARylation

Kang, M., Park, S., Park, S., Lee, H. G., & Park, J. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179826 · Cited by 48

Investigational drugs for the treatment of cervical cancer

Barra, F., Lorusso, D., Maggiore, U. L. R., Ditto, A., Bogani, G., Raspagliesi, F., & Ferrero, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1302427 · Cited by 46

Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration

Wangpaichitr, M., Theodoropoulos, G., Nguyen, D. J. M., Wu, C., Spector, S. A., Feun, L. G., & Savaraj, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147379 · Cited by 44

Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer

Eskander, R. N., & Tewari, K. S. (2014) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2014.25.3.249 · Cited by 42

PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data

Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 45

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib

Bianchi, A., Lopez, S., Altwerger, G. H., Bellone, S., Bonazzoli, E., Zammataro, L. A., Manzano, A., Manara, P., Perrone, E., Zeybek, B., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.08.010 · Cited by 42

Cisplatin in the era of PARP inhibitors and immunotherapy

Duan, M., Leng, S., & Mao, P. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108642 · Cited by 45

DNA repair and the contribution to chemotherapy resistance

Nesic, K., Parker, P., Swisher, E. M., & Krais, J. J. (2025) · Genome Medicine · doi:10.1186/s13073-025-01488-8 · Cited by 57

MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1

Luo, Y.-S., Tong, L., Meng, H., Zhu, W., Guo, L., Wei, T., & Zhang, J. (2016) · Gene · doi:10.1016/j.gene.2016.11.031 · Cited by 41

The oncolytic peptide LTX-315 triggers necrotic cell death

Forveille, S., Zhou, H., Sauvat, A., Bezu, L., Müller, K., Liu, P., Zitvogel, L., Pierron, G., Rekdal, Ø., Kepp, O., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1093710 · Cited by 41

Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance

Sourisseau, T., Hélissey, C., Lefèbvre, C., Ponsonnailles, F., Malka-Mahieu, H., Olaussen, K. A., André, F., Vagner, S., & Soria, J. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1120918 · Cited by 38

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy

Lorusso, D., Tripodi, E., Maltese, G., Lepori, S., Sabatucci, I., Bogani, G., & Raspagliesi, F. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s124447 · Cited by 36

Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold

Giannini, G., Battistuzzi, G., Vesci, L., Milazzo, F. M., Paolis, F. D., Barbarino, M., Guglielmi, M. B., Carollo, V., Gallo, G., Artali, R., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.048 · Cited by 36

The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors

Alemasova, E. E., Naumenko, K. N., Kurgina, T. A., Anarbaev, R. O., & Lavrik, O. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25158 · Cited by 36

Karyotypic Aberrations in Oncogenesis and Cancer Therapy

Vitale, I., Manic, G., Senovilla, L., Kroemer, G., & Galluzzi, L. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.08.001 · Cited by 34

Dual Approaches in Oncology: The Promise of siRNA and Chemotherapy Combinations in Cancer Therapies

Sousa, C., & Videira, M. (2025) · Onco · doi:10.3390/onco5010002 · Cited by 39

PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix

Mann, M., Kumar, S., Sharma, A. K., Chauhan, S. S., Bhatla, N., Kumar, S., Bakhshi, S., Gupta, R., & Kumar, L. (2019) · Oncotarget · doi:10.18632/oncotarget.27008 · Cited by 34

Quantification of cellular viability by automated microscopy and flow cytometry

Sauvat, A., Wang, Y., Segura, F., Spaggiari, S., Müller, K., Zhou, H., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3266 · Cited by 30

Intricatinol synergistically enhances the anticancerous activity of cisplatin in human A549 cells via p38 MAPK/p53 signalling

Singh, V. K., Arora, D., Satija, N. K., Khare, P., Roy, S. K., & Sharma, P. K. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1404-0 · Cited by 31

Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells

Wang, Q., Xiong, J., Qiu, D., Zhao, X. B., Yan, D., Xu, W., Wang, Z., Chen, Q., Panday, S., Li, A., et al. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.08.001 · Cited by 31

Viability inhibition effect of gambogic acid combined with cisplatin on osteosarcoma cells via mitochondria-independent apoptotic pathway

Zhao, W., You, C., Zhuang, J., Zu, J., Chi, Z., Xu, G., & Yan, J. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1740-5 · Cited by 30

Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy

Xie, K., He, H., Sun, A., Liu, X.-B., Sun, L. L., & Dong, X.-J. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.6.2591 · Cited by 30

Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer

Michels, J., Adam, J., Goubar, A., Obrist, F., Damotte, D., Robin, A., Alifano, M., Vitale, I., Olaussen, K. A., Girard, P., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv393 · Cited by 31

Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling

Fatima, I., Ayachi, I. E., Playa, H. C., Alva-Ornelas, J. A., Khalid, A. B., Kuenzinger, W. L., Wend, P., Pence, J. C., Brakefield, L., Krutilina, R. I., et al. (2019) · Cancers · doi:10.3390/cancers11122039 · Cited by 30

Cervical cancer: a tale from HPV infection to PARP inhibitors

Mann, M., Singh, V. P., & Kumar, L. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.09.014 · Cited by 31

Targeted drug conjugate systems for ovarian cancer chemotherapy

Ogundipe, O. D., Olajubutu, O., & Adesina, S. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115151 · Cited by 29

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use

Lim, D. G. S., & Ngeow, J. Y. Y. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0116 · Cited by 28

Systems biology approaches to develop innovative strategies for lung cancer therapy

Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.28 · Cited by 27

MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance

Wang, J., Kho, D., Zhou, J.-Y., Davis, R. J., & Wu, G. S. (2017) · Oncogene · doi:10.1038/onc.2017.197 · Cited by 28

Reversal of Cisplatin Resistance in Ovarian Cancer by the Multitargeted Nanodrug Delivery System Tf-Mn-MOF@Nira@CDDP

Liu, Y., Wang, Y., Guan, X., Wu, Q., Zhang, M., Cui, P., Wang, C., Chen, X., Meng, X., & Ma, T. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c05374 · Cited by 27

Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer

Wolford, J. E., & Tewari, K. S. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1443074 · Cited by 27

Mixed copper–platinum complex formation could explain synergistic antiproliferative effect exhibited by binary mixtures of cisplatin and copper-1,10-phenanthroline compounds: An ESI–MS study

Pivetta, T., Lallai, V., Valletta, E., Trudu, F., Isaia, F., Perra, D., Pinna, E., & Pani, A. (2015) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2015.05.004 · Cited by 27

Chemotherapy for advanced gastric cancer: future perspective in Japan

Shitara, K. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0648-7 · Cited by 26

Alkannin-Induced Oxidative DNA Damage Synergizes With PARP Inhibition to Cause Cancer-Specific Cytotoxicity

Ming-xin, C., Wang, H., Niu, J., Song, Y., & Zou, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.610205 · Cited by 26

Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer

Shitara, K., & Ohtsu, A. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0138 · Cited by 25

Targeting cervical cancer: Is there a role for poly (ADP‐ribose) polymerase inhibition?

Tomao, F., Santangelo, G., Musacchio, L., Donato, V. D., Fischetti, M., Giancotti, A., Perniola, G., Petrella, M. C., Monti, M., Palaia, I., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29440 · Cited by 26

Rational design of anticancer platinum(IV) prodrugs

Zhang, S., Wang, X., & Guo, Z. (2019) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2019.10.009 · Cited by 25

Elemental bioimaging of Cisplatin inCaenorhabditis elegansby LA-ICP-MS

Crone, B., Aschner, M., Schwerdtle, T., Kärst, U., & Bornhorst, J. (2015) · Metallomics · doi:10.1039/c5mt00096c · Cited by 25

Trial watch – inhibiting PARP enzymes for anticancer therapy

Sistigu, A., Manic, G., Obrist, F., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1053594 · Cited by 25

Morin Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy

Singh, M. P., Khaket, T. P., Bajpai, V. K., Alfarraj, S. A., Kim, S.-G., Chen, L., Huh, Y. S., Han, Y.-K., & Kang, S. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218253 · Cited by 24

Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers

Lombardi, A. J., Hoskins, E. E., Foglesong, G. D., Wikenheiser‐Brokamp, K. A., Wiesmüller, L., Hanenberg, H., Andreassen, P. R., Jacobs, A. J., Olson, S. B., Keeble, W. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2616 · Cited by 23

[18F]-SuPAR: A Radiofluorinated Probe for Noninvasive Imaging of DNA Damage-Dependent Poly(ADP-ribose) Polymerase Activity

Shuhendler, A. J., Cui, L., Chen, Z., Shen, B., Chen, M., James, M. L., Witney, T. H., Bazalova‐Carter, M., Gambhir, S. S., Chin, F. T., et al. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00089 · Cited by 23

Impaired DNA double‐strand breaks repair by kinesin family member 4A inhibition renders human H1299 non‐small‐cell lung cancer cells sensitive to cisplatin

Wan, Q., Shen, Y., Zhao, H., Wang, B., Zhao, L., Zhang, Y., Bu, X., Wan, M., & Shen, C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27703 · Cited by 22

BAP1 In Solid Tumors

Nunno, V. D., Frega, G., Santoni, M., Gatto, L., Fiorentino, M., Montironi, R., Battelli, N., Brandi, G., & Massari, F. (2019) · Future Oncology · doi:10.2217/fon-2018-0915 · Cited by 22

Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer

Zhang, F., Shen, M., Li, Y., Yang, X., Tsai, Y., Keng, P. C., Chen, Y., Lee, S. O., & Chen, Y. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1345391 · Cited by 22

Drugging cancer metabolism: Expectations vs. reality

Montrose, D. C., & Galluzzi, L. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.07.007 · Cited by 21

Abstract 2152: PJ34-mediated PARP-1 enzymatic activity inhibition in cervical cancer modulates the cellular response to cisplatin

Mann, M., Chauhan, S. S., Kumar, S., Bhatla, N., Bakhshi, S., Gupta, R., Iqbal, S., & Kumar, L. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2152

MCL-1 dependency of cisplatin-resistant cancer cells

Michels, J., Obrist, F., Vitale, I., Lissa, D., Garcia, P., Behnam‐Motlagh, P., Kohno, K., Wu, G. S., Brenner, C., Castedo, M., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.029 · Cited by 68

Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells

Wang, Q., Xiong, J., Qiu, D., Zhao, X. B., Yan, D., Xu, W., Wang, Z., Chen, Q., Panday, S., Li, A., et al. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.08.001 · Cited by 31

Effect of PARP inhibitors on the proliferation inhibition by cisplatin in lung cancer cell lines

Liu, J. L., Sun, R., Li, W. H., Wang, Y., Cai, X. Y., & Jiang, W. (2012) · Zhonghua zhongliu fangzhi zazhi

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Michels, J., Vitale, I., Senovilla, L., Enot, D. P., Garcia, P., Lissa, D., Olaussen, K. A., Brenner, C., Soria, J., Castedo, M., et al. (2013) · Cell Cycle · doi:10.4161/cc.24034 · Cited by 78